Evropska unija - slovenščina - EMA (European Medicines Agency)

amarin pharmaceuticals ireland limited - icosapent ethyl - dislipidemije - sredstva za spreminjanje lipidov - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostični radiofarmacevtiki - to zdravilo je samo za diagnostično uporabo. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. pri odraslih bolnikih, za pomoč pri razlikovanju verjetno, demenco z lewy organe, od alzheimerjeve bolezni.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - drugi zdravljene bolezni prebavil in presnove izdelki, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Evropska unija - slovenščina - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, črevesne protivnetna / antiinfective agenti - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.

Evropska unija - slovenščina - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - cepiva - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ferring gmbh - budezonid - tableta s podaljšanim sproščanjem - budezonid 9 mg / 1 tableta - budezonid

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

belupo, d.o.o., ljubljana - oksazepam - tableta - oksazepam 10 mg / 1 tableta - oksazepam

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lenis d.o.o. - hidroklorotiazid; lizinopril - tableta - hidroklorotiazid 12,5 mg / 1 tableta  lizinopril20 mg / 1 tableta; lizinopril 20 mg / 1 tableta - lizinopril in diuretiki

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

belupo, d.o.o., ljubljana - laktuloza, tekoča - sirup - laktuloza, tekoča 0,667 g / 1 ml - laktuloza